Clavis Pharma ASA : Appointments of Interim Chairman and Acting CEO

Clavis Pharma ASA : Appointments of Interim Chairman and Acting CEO

Oslo, Norway, 22 May 2013

Clavis Pharma ASA (OSE: CLAVIS), announces that the Board of Directors of Clavis Pharma has appointed Martin Nes, a board member of the Company, as Interim Chairman of the Board of Directors. Mr Nes replaces Anders P. Wiklund, who resigned from the Board of Directors effective 21 May 2013.  

The Board has also appointed Gunnar Manum, the CFO of Clavis Pharma, to the additional position of Acting CEO, until a long-term strategic solution is found for the Company.

Contacts:

Gunnar Manum

Chief Financial Officer

+47 24 11 09 71

+47 95 17 91 90 (mob)

[email protected]

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.